Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Evolution of diversity at the major histocompatibility complex.

Trends in ecology & evolution

Potts WK, Wakeland EK.
PMID: 21232350
Trends Ecol Evol. 1990 Jun;5(6):181-7. doi: 10.1016/0169-5347(90)90207-T.

Recent evidence from both population data and DNA sequence analyses indicates that the unprecedented genetic diversity found at MHC loci is selectively maintained in contemporary natural populations, although the strength and nature of this selection are currently unclear. Due...

Cite
Potts WK, Wakeland EK. Evolution of diversity at the major histocompatibility complex. Trends Ecol Evol. 1990;5(6):181-7doi: 10.1016/0169-5347(90)90207-T.
Potts, W. K., & Wakeland, E. K. (1990). Evolution of diversity at the major histocompatibility complex. Trends in ecology & evolution, 5(6), 181-7. https://doi.org/10.1016/0169-5347(90)90207-T
Potts, W K, and Wakeland, E K. "Evolution of diversity at the major histocompatibility complex." Trends in ecology & evolution vol. 5,6 (1990): 181-7. doi: https://doi.org/10.1016/0169-5347(90)90207-T
Potts WK, Wakeland EK. Evolution of diversity at the major histocompatibility complex. Trends Ecol Evol. 1990 Jun;5(6):181-7. doi: 10.1016/0169-5347(90)90207-T. PMID: 21232350.
Copy Download .nbib Format: NLM
Teen driver system modeling: a tool for policy analysis.

Injury epidemiology

Missikpode C, Peek-Asa C, McGehee DV, Torner J, Wakeland W, Wallace R.
PMID: 30221317
Inj Epidemiol. 2018 Sep 17;5(1):34. doi: 10.1186/s40621-018-0164-9.

BACKGROUND: Motor vehicle crashes remain the leading cause of teen deaths in spite of preventive efforts. Prevention strategies could be advanced through new analytic approaches that allow us to better conceptualize the complex processes underlying teen crash risk. This...

Cite
Missikpode C, Peek-Asa C, McGehee DV, et al. Teen driver system modeling: a tool for policy analysis. Inj Epidemiol. 2018;5(1):34doi: 10.1186/s40621-018-0164-9.
Missikpode, C., Peek-Asa, C., McGehee, D. V., Torner, J., Wakeland, W., & Wallace, R. (2018). Teen driver system modeling: a tool for policy analysis. Injury epidemiology, 5(1), 34. https://doi.org/10.1186/s40621-018-0164-9
Missikpode, Celestin, et al. "Teen driver system modeling: a tool for policy analysis." Injury epidemiology vol. 5,1 (2018): 34. doi: https://doi.org/10.1186/s40621-018-0164-9
Missikpode C, Peek-Asa C, McGehee DV, Torner J, Wakeland W, Wallace R. Teen driver system modeling: a tool for policy analysis. Inj Epidemiol. 2018 Sep 17;5(1):34. doi: 10.1186/s40621-018-0164-9. PMID: 30221317; PMCID: PMC6139293.
Copy Download .nbib Format: NLM
Reply.

Pain

Geissert P, Hallvik S, O'Kane N, Van Otterloo J, Alley L, Carson J, Leichtling G, Hildebran C, Wakeland W, Deyo RA.
PMID: 29557902
Pain. 2018 Apr;159(4):805-806. doi: 10.1097/j.pain.0000000000001156.

No abstract available.

Cite
Geissert P, Hallvik S, O'Kane N, et al. Reply. Pain. 2018;159(4):805-806doi: 10.1097/j.pain.0000000000001156.
Geissert, P., Hallvik, S., O'Kane, N., Van Otterloo, J., Alley, L., Carson, J., Leichtling, G., Hildebran, C., Wakeland, W., & Deyo, R. A. (2018). Reply. Pain, 159(4), 805-806. https://doi.org/10.1097/j.pain.0000000000001156
Geissert, Peter, et al. "Reply." Pain vol. 159,4 (2018): 805-806. doi: https://doi.org/10.1097/j.pain.0000000000001156
Geissert P, Hallvik S, O'Kane N, Van Otterloo J, Alley L, Carson J, Leichtling G, Hildebran C, Wakeland W, Deyo RA. Reply. Pain. 2018 Apr;159(4):805-806. doi: 10.1097/j.pain.0000000000001156. PMID: 29557902; PMCID: PMC5875708.
Copy Download .nbib Format: NLM
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.

Cell

Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P, Khan S, Obermoser G, Blankenship D, Wakeland E, Nassi L, Gotte A, Punaro M, Liu YJ, Banchereau J, Rossello-Urgell J, Wright T, Pascual V.
PMID: 27259156
Cell. 2016 Jun 02;165(6):1548-1550. doi: 10.1016/j.cell.2016.05.057.

No abstract available.

Cite
Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016;165(6):1548-1550doi: 10.1016/j.cell.2016.05.057.
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A. M., Acs, P., Turner, J., Anguiano, E., Vinod, P., Khan, S., Obermoser, G., Blankenship, D., Wakeland, E., Nassi, L., Gotte, A., Punaro, M., Liu, Y. J., Banchereau, J., Rossello-Urgell, J., Wright, T., & Pascual, V. (2016). Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell, 165(6), 1548-1550. https://doi.org/10.1016/j.cell.2016.05.057
Banchereau, Romain, et al. "Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients." Cell vol. 165,6 (2016): 1548-1550. doi: https://doi.org/10.1016/j.cell.2016.05.057
Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P, Khan S, Obermoser G, Blankenship D, Wakeland E, Nassi L, Gotte A, Punaro M, Liu YJ, Banchereau J, Rossello-Urgell J, Wright T, Pascual V. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016 Jun 02;165(6):1548-1550. doi: 10.1016/j.cell.2016.05.057. PMID: 27259156.
Copy Download .nbib Format: NLM
Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.

Molecular neuropsychiatry

Gadad BS, Raj P, Jha MK, Carmody T, Dozmorov I, Mayes TL, Wakeland EK, Trivedi MH.
PMID: 29998114
Mol Neuropsychiatry. 2018 Jun;4(1):7-19. doi: 10.1159/000487321. Epub 2018 May 03.

Genome-wide association studies (GWAS) were conducted in participants of the CO-MED (Combining Medications to Enhance Depression Outcomes) trial, a randomized, 3-treatment arm clinical trial of major depressive disorder (MDD) designed to identify markers of differential treatment outcome (response and...

Cite
Gadad BS, Raj P, Jha MK, et al. Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Mol Neuropsychiatry. 2018;4(1):7-19doi: 10.1159/000487321.
Gadad, B. S., Raj, P., Jha, M. K., Carmody, T., Dozmorov, I., Mayes, T. L., Wakeland, E. K., & Trivedi, M. H. (2018). Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Molecular neuropsychiatry, 4(1), 7-19. https://doi.org/10.1159/000487321
Gadad, Bharathi S, et al. "Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial." Molecular neuropsychiatry vol. 4,1 (2018): 7-19. doi: https://doi.org/10.1159/000487321
Gadad BS, Raj P, Jha MK, Carmody T, Dozmorov I, Mayes TL, Wakeland EK, Trivedi MH. Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Mol Neuropsychiatry. 2018 Jun;4(1):7-19. doi: 10.1159/000487321. Epub 2018 May 03. PMID: 29998114; PMCID: PMC6032036.
Copy Download .nbib Format: NLM
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J.
PMID: 34551906
Clin Cancer Res. 2021 Dec 15;27(24):6716-6725. doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22.

PURPOSE: This phase II clinical trial evaluated whether the addition of stereotactic ablative radiotherapy (SAbR), which may promote tumor antigen presentation, improves the overall response rate (ORR) to high-dose IL2 (HD IL2) in metastatic renal cell carcinoma (mRCC).PATIENTS AND...

Cite
Hannan R, Mohamad O, Diaz de Leon A, et al. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021;27(24):6716-6725doi: 10.1158/1078-0432.CCR-21-2083.
Hannan, R., Mohamad, O., Diaz de Leon, A., Manna, S., Pop, L. M., Zhang, Z., Mannala, S., Christie, A., Christley, S., Monson, N., Ishihara, D., Hsu, E. J., Ahn, C., Kapur, P., Chen, M., Arriaga, Y., Courtney, K., Cantarel, B., Wakeland, E. K., Fu, Y. X., Pedrosa, I., Cowell, L., Wang, T., Margulis, V., Choy, H., Timmerman, R. D., & Brugarolas, J. (2021). Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6716-6725. https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan, Raquibul, et al. "Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6716-6725. doi: https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Dec 15;27(24):6716-6725. doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22. PMID: 34551906.
Copy Download .nbib Format: NLM
Validation of a spatial agent-based model for Taenia solium transmission ("CystiAgent") against a large prospective trial of control strategies in northern Peru.

PLoS neglected tropical diseases

Pray IW, Pizzitutti F, Bonnet G, Gonzales-Gustavson E, Wakeland W, Pan WK, Lambert WE, Gonzalez AE, Garcia HH, O'Neal SE.
PMID: 34705827
PLoS Negl Trop Dis. 2021 Oct 27;15(10):e0009885. doi: 10.1371/journal.pntd.0009885. eCollection 2021 Oct.

BACKGROUND: The pork tapeworm (Taenia solium) is a parasitic helminth that imposes a major health and economic burden on poor rural populations around the world. As recognized by the World Health Organization, a key barrier for achieving control of...

Cite
Pray IW, Pizzitutti F, Bonnet G, et al. Validation of a spatial agent-based model for Taenia solium transmission ("CystiAgent") against a large prospective trial of control strategies in northern Peru. PLoS Negl Trop Dis. 2021;15(10):e0009885doi: 10.1371/journal.pntd.0009885.
Pray, I. W., Pizzitutti, F., Bonnet, G., Gonzales-Gustavson, E., Wakeland, W., Pan, W. K., Lambert, W. E., Gonzalez, A. E., Garcia, H. H., O'Neal, S. E. (2021). Validation of a spatial agent-based model for Taenia solium transmission ("CystiAgent") against a large prospective trial of control strategies in northern Peru. PLoS neglected tropical diseases, 15(10), e0009885. https://doi.org/10.1371/journal.pntd.0009885
Pray, Ian W, et al. "Validation of a spatial agent-based model for Taenia solium transmission ("CystiAgent") against a large prospective trial of control strategies in northern Peru." PLoS neglected tropical diseases vol. 15,10 (2021): e0009885. doi: https://doi.org/10.1371/journal.pntd.0009885
Pray IW, Pizzitutti F, Bonnet G, Gonzales-Gustavson E, Wakeland W, Pan WK, Lambert WE, Gonzalez AE, Garcia HH, O'Neal SE. Validation of a spatial agent-based model for Taenia solium transmission ("CystiAgent") against a large prospective trial of control strategies in northern Peru. PLoS Negl Trop Dis. 2021 Oct 27;15(10):e0009885. doi: 10.1371/journal.pntd.0009885. eCollection 2021 Oct. PMID: 34705827; PMCID: PMC8575314.
Copy Download .nbib Format: NLM
Diverse Autonomic Nervous System Stress Response Patterns in Childhood Sensory Modulation.

Frontiers in integrative neuroscience

Christensen JS, Wild H, Kenzie ES, Wakeland W, Budding D, Lillas C.
PMID: 32132906
Front Integr Neurosci. 2020 Feb 18;14:6. doi: 10.3389/fnint.2020.00006. eCollection 2020.

The specific role of the autonomic nervous system (ANS) in emotional and behavioral regulation-particularly in relation to automatic processes-has gained increased attention in the sensory modulation literature. This mini-review article summarizes current knowledge about the role of the ANS...

Cite
Christensen JS, Wild H, Kenzie ES, et al. Diverse Autonomic Nervous System Stress Response Patterns in Childhood Sensory Modulation. Front Integr Neurosci. 2020;14:6doi: 10.3389/fnint.2020.00006.
Christensen, J. S., Wild, H., Kenzie, E. S., Wakeland, W., Budding, D., & Lillas, C. (2020). Diverse Autonomic Nervous System Stress Response Patterns in Childhood Sensory Modulation. Frontiers in integrative neuroscience, 146. https://doi.org/10.3389/fnint.2020.00006
Christensen, Jacquelyn S, et al. "Diverse Autonomic Nervous System Stress Response Patterns in Childhood Sensory Modulation." Frontiers in integrative neuroscience vol. 14 (2020): 6. doi: https://doi.org/10.3389/fnint.2020.00006
Christensen JS, Wild H, Kenzie ES, Wakeland W, Budding D, Lillas C. Diverse Autonomic Nervous System Stress Response Patterns in Childhood Sensory Modulation. Front Integr Neurosci. 2020 Feb 18;14:6. doi: 10.3389/fnint.2020.00006. eCollection 2020. PMID: 32132906; PMCID: PMC7040227.
Copy Download .nbib Format: NLM
ANSWER: Annotation Software for Electronic Reporting.

JCO clinical cancer informatics

Raulerson C, Jimenez G, Wakeland B, Villa E, Sorelle J, Malter J, Gagan J, Cantarel B.
PMID: 35025668
JCO Clin Cancer Inform. 2022 Jan;6:e2100113. doi: 10.1200/CCI.21.00113.

PURPOSE: To better use genetic testing, which is used by clinicians to explain the molecular mechanism of disease and to suggest clinical actionability and new treatment options, clinical next-generation sequencing (NGS) laboratories must send the results into reports in...

Cite
Raulerson C, Jimenez G, Wakeland B, et al. ANSWER: Annotation Software for Electronic Reporting. JCO Clin Cancer Inform. 2022;6:e2100113doi: 10.1200/CCI.21.00113.
Raulerson, C., Jimenez, G., Wakeland, B., Villa, E., Sorelle, J., Malter, J., Gagan, J., & Cantarel, B. (2022). ANSWER: Annotation Software for Electronic Reporting. JCO clinical cancer informatics, 6e2100113. https://doi.org/10.1200/CCI.21.00113
Raulerson, Chelsea, et al. "ANSWER: Annotation Software for Electronic Reporting." JCO clinical cancer informatics vol. 6 (2022): e2100113. doi: https://doi.org/10.1200/CCI.21.00113
Raulerson C, Jimenez G, Wakeland B, Villa E, Sorelle J, Malter J, Gagan J, Cantarel B. ANSWER: Annotation Software for Electronic Reporting. JCO Clin Cancer Inform. 2022 Jan;6:e2100113. doi: 10.1200/CCI.21.00113. PMID: 35025668.
Copy Download .nbib Format: NLM
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J.
PMID: 34551906
Clin Cancer Res. 2021 Sep 22; doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22.

PURPOSE: This phase II clinical trial evaluated whether the addition of stereotactic ablative radiotherapy (SAbR), which may promote tumor antigen presentation, improves the overall response rate (ORR) to high-dose IL2 (HD IL2) in metastatic renal cell carcinoma (mRCC).PATIENTS AND...

Cite
Hannan R, Mohamad O, Diaz de Leon A, et al. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-2083.
Hannan, R., Mohamad, O., Diaz de Leon, A., Manna, S., Pop, L. M., Zhang, Z., Mannala, S., Christie, A., Christley, S., Monson, N., Ishihara, D., Hsu, E. J., Ahn, C., Kapur, P., Chen, M., Arriaga, Y., Courtney, K., Cantarel, B., Wakeland, E. K., Fu, Y. X., Pedrosa, I., Cowell, L., Wang, T., Margulis, V., Choy, H., Timmerman, R. D., & Brugarolas, J. (2021). Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan, Raquibul, et al. "Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Sep 22; doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22. PMID: 34551906.
Copy Download .nbib Format: NLM
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J.
PMID: 34551906
Clin Cancer Res. 2021 Dec 15;27(24):6716-6725. doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22.

PURPOSE: This phase II clinical trial evaluated whether the addition of stereotactic ablative radiotherapy (SAbR), which may promote tumor antigen presentation, improves the overall response rate (ORR) to high-dose IL2 (HD IL2) in metastatic renal cell carcinoma (mRCC).PATIENTS AND...

Cite
Hannan R, Mohamad O, Diaz de Leon A, et al. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021;27(24):6716-6725doi: 10.1158/1078-0432.CCR-21-2083.
Hannan, R., Mohamad, O., Diaz de Leon, A., Manna, S., Pop, L. M., Zhang, Z., Mannala, S., Christie, A., Christley, S., Monson, N., Ishihara, D., Hsu, E. J., Ahn, C., Kapur, P., Chen, M., Arriaga, Y., Courtney, K., Cantarel, B., Wakeland, E. K., Fu, Y. X., Pedrosa, I., Cowell, L., Wang, T., Margulis, V., Choy, H., Timmerman, R. D., & Brugarolas, J. (2021). Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6716-6725. https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan, Raquibul, et al. "Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6716-6725. doi: https://doi.org/10.1158/1078-0432.CCR-21-2083
Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Dec 15;27(24):6716-6725. doi: 10.1158/1078-0432.CCR-21-2083. Epub 2021 Sep 22. PMID: 34551906.
Copy Download .nbib Format: NLM
Humoral and cellular correlates of a novel immune-related adverse event and its treatment.

Journal for immunotherapy of cancer

Gonugunta AS, von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE.
PMID: 34880115
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003585.

Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a...

Cite
Gonugunta AS, von Itzstein MS, Mu-Mosley H, et al. Humoral and cellular correlates of a novel immune-related adverse event and its treatment. J Immunother Cancer. 2021;9(12)doi: 10.1136/jitc-2021-003585.
Gonugunta, A. S., von Itzstein, M. S., Mu-Mosley, H., Fattah, F., Farrar, J. D., Mobely, A., Rashdan, S., Lai, S., Bhai, S. F., Bermas, B. L., Karp, D., Li, Q. Z., Wakeland, E. K., & Gerber, D. E. (2021). Humoral and cellular correlates of a novel immune-related adverse event and its treatment. Journal for immunotherapy of cancer, 9(12), . https://doi.org/10.1136/jitc-2021-003585
Gonugunta, Amrit S, et al. "Humoral and cellular correlates of a novel immune-related adverse event and its treatment." Journal for immunotherapy of cancer vol. 9,12 (2021). doi: https://doi.org/10.1136/jitc-2021-003585
Gonugunta AS, von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE. Humoral and cellular correlates of a novel immune-related adverse event and its treatment. J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003585. PMID: 34880115; PMCID: PMC8655605.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries